# Clinical Study of Oral IGF-1R Inhibitor in Subjects With Advanced Refractory Solid Tumors

> **NCT01779336** · PHASE1 · SUSPENDED · sponsor: **Piramal Enterprises Limited** · enrollment: 70 (estimated)

## Conditions studied

- Advanced Refractory Solid Tumors

## Interventions

- **DRUG:** PL225B

## Key facts

- **NCT ID:** NCT01779336
- **Lead sponsor:** Piramal Enterprises Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2012-12
- **Primary completion:** 2014-11
- **Final completion:** 2014-12
- **Target enrollment:** 70 (ESTIMATED)
- **Why stopped:** Sponsor decision not related to patient safety
- **Last updated:** 2014-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01779336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01779336, "Clinical Study of Oral IGF-1R Inhibitor in Subjects With Advanced Refractory Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01779336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*